ClinicalTrials.gg
TerminatedNCT05660967EPCORE DLBCL-3Updated Oct 23, 2026

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Epcoritamab and Lenalidomide in Diffuse Large B-Cell Lymphoma, sponsored by Genmab. Terminated at 74 sites in 12 countries. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
7th of 24
111 · median 41
Started
2023
with 1 other
Phase 2
14 of 24
12 open now
Registered
6th of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 14 in phase 2, and was the 6th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Read the detailed description

This is an open-label, multicenter, global phase-2 trial evaluating the efficacy and safety of epcoritamab monotherapy and epcoritamab plus lenalidomide in elderly patients who are deemed anthracycline ineligible.

The trial is designed in two stages:

  • Stage 1 which includes a safety run-in phase in each arm
  • Stage 2, an expansion of the selected treatment from Stage 1
03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Double-hit lymphoma
  • Triple-hit lymphoma
  • Follicular grade 3B
  • T-cell/histiocyte rich LBCL
  • DuoBody®
  • Anti-CD3
  • Anti-CD20
  • Subcutaneous
  • Bispecific antibody
  • EPCORE
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have newly diagnosed CD20+ large cell lymphoma.
  • Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy due to:

    • Being age ≥80 years; AND/OR
    • Being age ≥75 years and having important comorbid condition(s), which are likely to have a negative impact on tolerability of anthracycline-based therapy/cytotoxic chemotherapy.
  • Have Immune Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of 10.
  • Have Ann Arbor Stage II-IV disease.
  • Have PS of 0, 1, or 2; (ECOG PS of 3 may be considered if impairment is attributed to current lymphoma/DLBCL and if pre-phase treatment during the screening phase results in an improvement of ECOG PS to ≤2 prior to enrollment).
  • Have as per Lugano criteria.
  • Have acceptable organ function based on baseline bloodwork.
  • Must have fresh (preferred) or archival material at screening.

Exclusion criteria

Exclusion Criteria:

  • Has known active, bacterial, viral, fungal, mycobacterial, parasitic, or other infection at trial enrollment, including COVID-19 infection.
  • Has severe cardiovascular disease (other than those eligibility criteria that preclude the subject from receiving anthracycline-based therapy/cytotoxic chemotherapy),
  • Has been exposed to/received any of the following prior therapies, treatments, or procedures within the specified timeframes:

    • Major surgery within 4 weeks prior to the first dose of epcoritamab;
    • Non- antineoplastic agents (except anti-CD20 monoclonal antibodies) or any investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab;
    • hematopoietic stem cell transplantation (HSCT), CAR-T, allogeneic stem cell transplantation, or solid organ transplantation;
    • Live, attenuated vaccines within 30 days prior to initiation of epcoritamab;
    • Investigational vaccines within 28 days before the planned first dose of epcoritamab (ie, experimental and/or non-authorized SARS-CoV-2 vaccinations and therapies are not allowed);
    • Invasive investigational medical device use within 28 days before the planned first dose of epcoritamab.
  • Has primary central nervous system (CNS) tumor or known CNS involvement or intracranial involvement as confirmed by mandatory brain magnetic resonance imaging/computed tomography (MRI/CT) scan at screening and, if clinically indicated, by lumbar puncture.
  • Has a seizure disorder requiring anti-epileptic therapy or experienced a seizure within 6 months of signing an form.
  • Has known past or current other than inclusion diagnosis, with exceptions as stated in protocol.
  • Has known or suspected allergies, , or intolerance to either of the trial treatments or has known or suspected to the use of all locally available anti-cytokine therapies per local guidelines for management of cytokine release syndrome (CRS).
  • Has active virus (HBV) (DNA polymerase chain reaction [PCR]-positive) or virus (HCV) (RNA PCR-positive) infection, current alcohol abuse, or cirrhosis.
  • Has active cytomegalovirus (CMV) infection (DNA PCR-positive) requiring treatment.
  • Has suspected active or inadequately treated latent tuberculosis.
  • Has a known history of seropositivity for . Note: HIV testing is required at screening only if required per local health authorities or institutional standards.

Note: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Epcoritamab monotherapy

    Biological: Epcoritamab

  • Experimental
    Epcoritamab in combination with lenalidomide

    Biological: Epcoritamab · Drug: Lenalidomide

Interventions

  • BiologicalEpcoritamab

    Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.

    Also known as: GEN3013, DuoBody®-CD3×CD20, EPKINLY™

  • Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.

    Also known as: Revlimid®

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) rate

    Percentage of participants achieving CR. Assessed by the Investigator per Lugano criteria

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

Secondary outcomes

  1. Duration of response (DOR)

    Defined as the time between date of first response to the date of first documented tumor progression or death (due to any cause) whichever occurs first

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  2. Duration of complete response (DOCR)

    Defined as the time between the date of first CR to the date of the first documented tumor progression or death due to any cause, whichever comes first

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  3. Time to response (TTR)

    Defined as the time from first dose to first documentation of objective tumor response (CR or PR)

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 1 year

  4. Overall Response Rate (ORR)

    Defined as the percentage of patients who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  5. Progression-free survival (PFS)

    Defined as the time from first dose to date of PD or death (due to any cause) whichever occurs first

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  6. Time to next anti-lymphoma therapy (TTNT)

    Defined as the time from first dose to administration of subsequent anti-lymphoma therapy

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  7. Rate of minimal residual disease (MRD) negativity

    Percentage of participants with at least 1 post-screening MRD negative result

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years

  8. Overall survival (OS)

    Defined at the timeframe from first dose to death

    Time frame: From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 3 years

  9. Incidence and severity of adverse events (AEs)

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment

    Time frame: From screening until end of the safety follow-up period (60 days after last dose)

  10. Incidence of anti-drug antibodies (ADAs) to epcoritamab in plasma

    To evaluate immunogenicity

    Time frame: From first dose until treatment discontinuation (assessed up to 12 months)

  11. Evaluate patient-reported outcomes (PROs) related to lymphoma symptoms

    Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym). Scale from 0-168 obtained by summing individual subscale scores. Higher scores for the scales indicate better quality of life

    Time frame: From cycle 1, day 1 until 90 days after last dose (each cycle is 28 days)

  12. Epcoritamab plasma concentrations over time

    Time frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)

07

Study locations

74 sites
  • UW Cancer Center at ProHealth Care
    Waukesha, Wisconsin 53188, United States
  • Kepler Universitätsklinikum
    Linz, Austria
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Wels, Austria
  • Institut Jules Bordet
    Anderlecht, Belgium
  • ZNA
    Antwerp, Belgium
  • UZ Brussels
    Jette, Belgium
  • UZ Leuven
    Leuven, Belgium
  • AZ Delta
    Roeselare, Belgium
  • Vitaz
    Temse, Belgium
  • AZ Turnhout - Campus Sint-Elisabeth
    Turnhout, Belgium
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, Czechia
  • Fakultni nemocnice v Motole
    Prague, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, Czechia
  • CHU Angers - Hôpital Hôtel Dieu
    Angers, France
  • Hôpital Henri Mondor
    Créteil, France
  • Hopital Claude Huriez - CHRU Lille
    Lille, France
  • Hopital de la Conception - APHM
    Marseille, France
  • CHU de Nantes - Hotel Dieu
    Nantes, France
  • Hôpital Saint-Antoine
    Paris, France
  • Hôpital Saint-Louis
    Paris, France
  • CHU de Bordeaux - Hôpital Haut-Lévêque
    Pessac, France
  • CHU Amiens - Hopital Sud
    Salouël, France
  • CHU Tours - Hôpital Bretonneau
    Tours, France
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Vivantes Klinikum Neukoelln
    Berlin, State of Berlin, Germany
  • Universitaetsklinikum Aachen AOeR
    Aachen, Germany
  • Universitaetsklinikum Wuerzburg
    Würzburg, Germany
  • Clinica di Ematologia AOU Ospedali Riuniti di Ancona
    Ancona, Ancona, Italy
  • IRCCS Centro di Riferimento Oncologico
    Aviano, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
    Brescia, Italy
  • Fondazione del Piemonte per l'Oncologia IRCC Candiolo
    Candiolo, Italy
  • IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST
    Meldola, Italy
  • IEO Istituto Europeo di Oncologia Parent
    Milan, Italy
  • Ospedale San Raffaele
    Milan, Italy
  • Azienda Ospedaliera Vincenzo Cervello
    Palermo, Italy
  • AUSL Piacenza Ospedale Guglielmo da Saliceto
    Piacenza, Italy
  • Azienda sanitaria integrata università di Trieste
    Trieste, Italy
  • Kyushu University Hospital
    Fukuoka, Japan
  • Kagoshima University Hospital
    Kagoshima, Japan
  • Kanazawa University Hospital
    Kanazawa, Japan
  • National Cancer Center Hospital East
    Kashiwa, Japan
  • Cancer Institute Hospital of JFCR
    Kōtoku, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama, Japan
  • NHO Nagoya Medical Center
    Nagoya, Japan
  • Kindai University Hospital
    Ōsaka-sayama, Japan
  • Yamagata University Hospital
    Yamagata, Japan
  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
    Biała Podlaska, Poland
  • Pratia MCM Krakow
    Krakow, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, Poland
  • MICS Centrum Medyczne Torun
    Torun, Poland
  • Keimyung University Dongsan Hospital
    Daegu, South Korea
  • National Cancer Center
    Goyang-si, South Korea
  • Jeonbuk National University Hospital
    Jeonju, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • ICO Badalona - Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • ICO l'Hospitalet - Hospital Duran i Reynals
    Barcelona, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Hospital Universitario Nuestra Señora de Valme
    Seville, Spain
  • Hospital Universitario Puerta del Mar
    Seville, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
  • Royal Marsden Hospital - Fulham
    London, United Kingdom
  • Derriford Hospital
    Plymouth, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
  • Royal Marsden Hospital
    Sutton, United Kingdom
  • Royal Cornwall Hospital NHS Trust
    Truro, United Kingdom
08

References and documents

Publications

  • Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, Lopez-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. Lancet Haematol. 2026 Jul;13(7):e435-e448. doi: 10.1016/S2352-3026(26)00112-2. Epub 2026 Jun 12. PubMed 42285113 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jun 2026, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 21, 2022
StartActual
Mar 6, 2023
Primary completionActual
Jun 10, 2026
CompletionActual
Jun 10, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 added, 5 removed
What changed in the outcomes
  • AddedEpcoritamab plasma concentrations over timeTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
  • RemovedIncidence of clinically significant shifts in laboratory parametersTime frame: From screening until end of the safety follow-up period (60 days after last dose)
  • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
  • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
  • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
  • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Secondary outcomes 1 added, 5 removed
    What changed in the outcomes
    • AddedEpcoritamab plasma concentrations over timeTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
    • RemovedIncidence of clinically significant shifts in laboratory parametersTime frame: From screening until end of the safety follow-up period (60 days after last dose)
    • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
    • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
    • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
    • RemovedAssess pharmacokinetics (PK) of epcoritamabTime frame: From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05660967
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Mar 6, 2023
Primary completion
Jun 10, 2026
Completion
Jun 10, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion